Druge izrazite patološke laboratorijske vrednosti (3. ali 4. stopnje), opisane pri ≥ 2 % bolnikih, ki so prejemali zdravilo REYATAZ in enega ali več NRTI- jev, so: zvišanje kreatin- kinaze (7 %), zvišanje alanin- aminotransferaze/ serumske glutamat- piruvat transaminaze (ALT/ SGPT) (4 %), zmanjšanje števila nevtrofilcev (4 %), zvišanje aspartat- aminotransferaze/ serumske glutamat- oksalacetat transaminaze (AST/ SGOT) (3 %) in zvišanje lipaze (2 %).
Other marked clinical laboratory abnormalities (Grade 3 or 4) reported in ≥ 2 % of patients receiving regimens containing REYATAZ and one or more NRTIs included: elevated creatine kinase (7 %), elevated alanine aminotransferase/ serum glutamic-pyruvic transaminase (ALT/ SGPT) (4 %), low neutrophils (4 %), elevated aspartate aminotransferase/ serum glutamic-oxaloacetic transaminase (AST/ SGOT) (3 %), and elevated lipase (2 %).